Cancer cell

Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes

Retrieved on: 
Thursday, April 4, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Diagnosis, PCR, Plasma, Carcinoma, Cancer cell, Protocol, Biomarker, DNA, Classification, University, MD Anderson Cancer Center, DNA methylation, AACR, Liquid biopsy, SCLC, Medical imaging

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes.

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes.
  • The Company is presenting the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, April 5-10.
  • The 13-marker PCR assay developed for this pilot study stemmed from data from a recent study published in Cancer Cell demonstrating the detection of SCLC using DNA methylation in plasma samples from heavy smokers, yielding a sensitivity of 94% and specificity of 95%.
  • In the data being presented at AACR, the 13-marker PCR assay correctly classified 97% of the SCLC tissue samples in a blinded cohort.

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, February 29, 2024
Research, Autoimmune disease, Anemia, Investment, Lung cancer, Patient, Mirvetuximab soravtansine, PLD, Cancer cell, AZA, Azacitidine, Neoplasm, Clinical trial, TP53, Fusion, Autoimmunity, G&A, Cancer research, NSCLC, AML, ASH, Inflammation, Conference, Safety, Collaboration, Pharmacokinetics, Insurance, Messenger, Research and development, Society, Event, Administration, Citigroup, Publication, Cancer, Pharmaceutical industry

Initial combination data from the Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC expected mid-year 2024.

Key Points: 
  • Initial combination data from the Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC expected mid-year 2024.
  • Shattuck Closes Financing: On December 21, 2023, Shattuck announced a $50 million public offering of common stock and concurrent private placement of pre-funded warrants.
  • Research and Development (R&D) Expenses: R&D expenses for the quarter ended December 31, 2023, were $15.2 million, as compared to $21.9 million for the quarter ended December 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the quarter ended December 31, 2023 were $4.4 million, as compared to $4.8 million for the quarter ended December 31, 2022.

Burning Rock Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 30, 2023
Lung cancer, Depreciation, Minimal, NGS, Food, Boehringer Ingelheim, MRD, Research, FDA, Hospital, CDX, Cancer cell, Breakthrough, NMPA, ID, Marketing, Investment, Webcast, Patient, NSCLC, Cryptocurrency

GUANGZHOU, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2023.

Key Points: 
  • GUANGZHOU, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2023.
  • Personalized Minimal Residual Disease (MRD) product, brPROPHETTM supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell in September 2023.
  • Total value of new contracts for the provision of pharma services entered into during the third quarter of 2023 amounted to RMB90 million, representing an 8% year-over-year increase.
  • Burning Rock will host a conference call to discuss the third quarter 2023 financial results at 7:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on November 30, 2023.

Altogen Labs Validates a Comprehensive Range of Lung Cancer Xenograft Animal Models for Cutting-Edge Oncology Research

Retrieved on: 
Friday, August 25, 2023
Human, Therapy, Genetics, CDX, SCID, Cancer, Lung cancer, PDX, Cancer cell, Patient, Vivo, Mouse, Diagnosis, NCI, Metastasis, Safety, Pharmaceutical industry, Medical imaging, Calu-3

AUSTIN, Texas, Aug. 25, 2023 /PRNewswire/ -- Altogen Labs, a preclinical CRO laboratory, has announced the validation of a comprehensive array of 10 lung cancer xenograft models.

Key Points: 
  • AUSTIN, Texas, Aug. 25, 2023 /PRNewswire/ -- Altogen Labs, a preclinical CRO laboratory, has announced the validation of a comprehensive array of 10 lung cancer xenograft models.
  • An array of lung cancer xenograft models can significantly improve the chances of a new lung cancer therapy being successful in humans, fewer therapies will fail in clinical trials, and more effective and less toxic lung cancer drugs will be developed.
  • Altogen Labs offers several PDX models and 10 in-house validated lung cancer xenograft models, including A549 , H460 , H226 , NCI-H1975 , DMS273 , LL/2 , Calu-3 , Calu-6 , H1155 , and NCI-H522 .
  • Altogen Labs array of lung cancer xenograft models provides a rich platform to capture the heterogeneity of lung cancer, reflecting its morphology, genetics, and stage-specific phenotypes.

Quibim, a company leveraging artificial intelligence to improve cancer diagnostics, makes key move into U.S. by hiring Boston-based chief medical officer

Retrieved on: 
Friday, May 26, 2023
Journal of Clinical Oncology, A.I, Abstract, The New England Journal of Medicine, Drug development, Clinical trial, Nature Communications, Cancer, Clinical Cancer Research, Skin cancer, Intelligence, MBA, CMO, Biomarker, IP, Mount Sinai Beth Israel, Harvard Medical School, Cancer cell, American Society of Clinical Oncology, Hospital, Journal, The Lancet, MD, Patient, Physician, Growth, American Cancer Society, Prostate cancer, Pharmaceutical industry, Medical imaging, Management, Medical device

BOSTON, May 26, 2023 /PRNewswire/ -- Catching cancer earlier and achieving more accurate initial diagnostics are two of the key benefits of breakthrough artificial intelligence technology that a European company is now bringing to U.S. patients. For Quibim, a leading provider of imaging technology in the E.U., that path began with the recent approval they received from the U.S. FDA to apply their patented A.I. powered technology to domestic prostate cancer diagnostics.

Key Points: 
  • The move signals a key juncture in the proliferation and mainstreaming of A.I.-based technology into the U.S. patient experience.
  • Now, the company is seeking to broaden those impacts in the U.S. with a chief medical officer at the helm who has deep ties to Massachusetts.
  • According to data adapted from the American Cancer Society and other sources by Cancer.net , prostate cancer is the most common cancer among men, except for skin cancer.
  • "Harmonization of medical solutions, particularly in imaging, to enhance real-world evidence interpretation and clinical trial reporting is critical.

Natera Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
Oncology, Medical Devices, Health, Consumer, Women, Genetics, DNA, SOFR, GAAP, Research, Medicare, Oportunidades, Blue Shield, Patient, Investment, Heart transplantation, UBS, Growth, III, SMART, NTRA, Breast cancer, Video game, Health insurance, Pharmaceutical industry, Cancer cell, Natera, Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2023.
  • Generated total revenues of $241.8 million in the first quarter of 2023, compared to $194.1 million in the first quarter of 2022, an increase of 24.5%.
  • Processed approximately 626,200 tests in the first quarter of 2023, compared to approximately 489,300 tests in the first quarter of 2022, an increase of 28.0%.
  • Performed 71,000 oncology tests in the first quarter of 2023, compared to approximately 35,100 units in the first quarter of 2022, an increase of 102.2%.

GRAIL CCGA Discovery Results Published in Cancer Cell Reveal Methylation as Promising DNA Hallmark for Multi-Cancer Early Detection

Retrieved on: 
Thursday, November 17, 2022
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Patient, Prostate-specific antigen, Cervical cancer, Blood, Ageing, Data science, Manuscript, United Kingdom, European Commission, College of American Pathologists, Senior, Methylation, European Society of Gynaecological Oncology, Nucleic acid thermodynamics, Annals of Oncology, Mammography, Machine learning, Clinical Laboratory, Criterion, Cloud computing, DNA, PSA, Cancer, Illumina, Inc., CCGA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mortality, Colonoscopy, American Joint Committee on Cancer, CLIA, College, Diagnosis, Oncology, Somatic mutation, Clod, Risk, Food, Medical imaging, Cancer cell, The McLoughlin Gallery, GRAIL

Findings were published online in Cancer Cell in a manuscript titled Evaluation of Cell-Free DNA Approaches for Multi-Cancer Early Detection.

Key Points: 
  • Findings were published online in Cancer Cell in a manuscript titled Evaluation of Cell-Free DNA Approaches for Multi-Cancer Early Detection.
  • The CCGA Discovery Substudy showed that among the evaluated classifiers, those using whole-genome methylation had one of the highest cancer signal detection sensitivities at 98% specificity.
  • Notably, CCGA Discovery identified methylation features in ct-DNA as having the leading combination of cancer detection and cancer signal origin performance.
  • False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur.

Global Research & Discovery Group Sciences, LLC Initiates Advance Research Project for Cancer

Retrieved on: 
Wednesday, September 7, 2022
Paradox, National, Human, Cancer, Polyphenol, Research, Cancer cell, EIS, Government, Life, Toxicity, Solution, Incidence, Body size and species richness, Risk, PIMS, DNA, Global Research, Cell, HAVEN, Thompson, Epidemic Intelligence Service, Whale, PIM, Peto's paradox, Pharmaceutical industry, Vaccine, Medicinal plants, Design, Linebacker

Then there are people like Daryl Thompson, founder and lead researcher of the Global Research and Discovery Group Sciences.

Key Points: 
  • Then there are people like Daryl Thompson, founder and lead researcher of the Global Research and Discovery Group Sciences.
  • "For 45 years, Peto's Paradox has been an unanswerable riddle that has loomed large in cancer research and treatment," said Thompson.
  • "I think it's time that we unravel this paradox and, I believe, in so doing, we'll turn the corner in the global fight against cancer."
  • Global Research and Discovery Group Sciences (GRDG) today announced the launch of Project Fastball, a multi-pronged effort to understand and solve Peto's paradox and, in so doing, provide a paradigm shift in how professionals view and treat cancer.

BostonGene Announces Publication in Cancer Cell Revealing the Development of a Machine Learning Cellular Deconvolution Algorithm that Accurately Reconstructs the Tumor Microenvironment and Supports Oncology Clinical Decision-making

Retrieved on: 
Tuesday, August 9, 2022
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Machine learning, Biomarker, Neoplasm, Standard of care, Cancer, PD-L1, Research, Blood, TME, Tumor microenvironment, RNA, Manuscript, Immunohistochemistry, Economics, Immunotherapy, RNA-Seq, Lung, Collection, MD, Medicine, Medical imaging, Cancer cell

These results indicate that cellular deconvolution can be utilized in future clinical applications to predict blood and tissue microenvironment composition, a critical factor in cancer pathogenesis, clinical outcome, and therapeutic resistance.

Key Points: 
  • These results indicate that cellular deconvolution can be utilized in future clinical applications to predict blood and tissue microenvironment composition, a critical factor in cancer pathogenesis, clinical outcome, and therapeutic resistance.
  • We look forward to further developing the Kassandra algorithm and showing its clinical applicability in precision oncology.
  • BostonGene Tumor PortraitTM Testsreveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.
  • Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

United States Pharmaceutical Contract Manufacturing Organization Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027) - ResearchAndMarkets.com

Retrieved on: 
Monday, May 9, 2022
Health, Pharmaceutical, COVID-19, Drug development, Catalent, Pharmacy, Calendar, Pharmaceutical Research and Manufacturers of America, Alzheimer's disease, ANDA, Pain, Biopharmaceutical, FDF, IND, RNA, Health informatics, Steroid, American Cancer Society, Food, Prevalence, Food and Drug Administration, Drug discovery, Alzheimer's Association, Immunotherapy, API, Thermo Fisher Scientific, BioNTech, Association, FDA, Inflammation, Investigational New Drug, Cancer, Diabetes, Anxiety, Enzyme, CMOS, Abbreviated New Drug Application, Adoption, Wall Street, Vaccine, CMO, Disease, Generic, IV, Chronic pain, CAGR, Insomnia, Infection, RNA transfection, Cancer cell, Clinical trial, USD, Fine chemical, Pharmaceutical industry, CBD, Growth

The "United States Pharmaceutical Contract Manufacturing Organization (CMO) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Pharmaceutical Contract Manufacturing Organization (CMO) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The US pharmaceutical contract manufacturing organization (CMO) market is expected to reach a CAGR of 5 % during the forecast period of 2022 to 2027.
  • As of 2019, more than 800 active Investigational New Drugs (IND) are waiting for approval with the FDA in the United States.
  • As of August 2019, 28% of the manufacturing facilities making APIs for the US markets are based in the United States.